Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 EBIT per Share is ₹ as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 683 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 146412.74% on this metric.
Avience Biomedicals's EBIT per Share for the
six
months ended in Mar. 2025 was ₹20.38.
Avience Biomedicals does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025.
During the past 12 months, the average EBIT per Share Growth Rate of Avience Biomedicals was 207.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Avience Biomedicals's EBIT per Share or its related term are showing as below:
NSE:AVIENCE's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Avience Biomedicals (NSE:AVIENCE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Avience Biomedicals EBIT per Share Related Terms
Avience Biomedicals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals (NSE:AVIENCE) has a EBIT per Share of ₹ as of Mar. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Avience Biomedicals and its competitors. According to the industry distribution chart, Avience Biomedicals ranks #999999 out of 683 companies in the Medical Devices & Instruments industry.
Is Avience Biomedicals' EBIT per Share too high?
Avience Biomedicals' current EBIT per Share is ₹. Based on the distribution chart, Avience Biomedicals ranks #999999 out of 683 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #999999 out of 683 companies for EBIT per Share. This places Avience Biomedicals in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current EBIT per Share is ₹. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current EBIT per Share of ₹. The current EBIT per Share is ₹. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current EBIT per Share is ₹ as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
